EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Radiotherapy plus lenvatinib versus radiotherapy plus sorafenib for hepatocellular carcinoma with portal vein tumor thrombus: a retrospective study

Min Zhang, Zhuangzhuang Zheng, Qiuhui Ding, Jing Su, Ying Xin, Xin Jiang

Frontiers in Pharmacology · 15.10.2024 · 15

DOI: 10.3389/fphar.2024.1458819 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 15.10.2024. Verfasst von Min Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Jilin Provincial Key Laboratory of Radiation Oncology and Therapy, The First Hospital of Jilin University and College of Basic Medical Science, Jilin…. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Portal vein tumor thrombus (PVTT) occurs frequently in hepatocellular carcinoma (HCC) patients. However, there is currently no satisfactory treatment. Radiotherapy (RT) and tyrosine kinase inhibitors (TKI) are currently commonly used. However, whether their combined use provides a survival benefit is debatable. This retrospective study compared the efficacy and safety between radiotherapy plus lenvatinib (RT + L) and radiotherapy plus sorafenib (RT + S) in the treatment of hepatocellular carcinoma with portal vein tumor thrombus (PVTT).

Methods

Among patients with PVTT who received RT + L or RT + S between March 2017 and September 2022, the primary endpoints were overall survival (OS) and progression-free survival (PFS). The secondary endpoints were objective response rate (ORR), disease control rate (DCR), and incidence of treatment-related adverse effects. The prognostic factors were also assessed.

Results

The analysis included 152 patients (RT + L: 48; RL: 25; RT + S: 55; S: 24). Compared with the RT + S group, the RT + L group had a longer OS and PFS. Among patients with type I/II PVTT, the median OS times were 19.8 months and 13.5 months ( p = 0.047) and the median PFS was 12.3 months and 7.3 months ( p = 0.042), respectively. And the median OS of the patients with type I/II PVTT were 14.4 months and 8.3 months ( p = 0.030) and the median PFS was 8.3 months and 6.2 months ( p = 0.026). ORR and DCR in RT + L group (25.0% and 75.0%) were also little higher than those in RT + S group (20.0% and 70.9%), but not statistically significant. In univariate analysis, etiology, Type of PVTT, alpha-fetoprotein (AFP) level, Child–Pugh score, and treatment method influenced OS. Multivariate analysis confirmed that treatment method, etiology, alpha-fetoprotein (AFP) level, and Child–Pugh score were independent prognostic factors for OS. Similar safety profiles were observed in the RT + L and RT + S groups. The most common adverse events were myelosuppression, decreased liver function, fatigue, diarrhea, nausea, and vomiting. Most adverse reactions were grade 1–2.

Conclusion

The side effects of radiotherapy plus lenvatinib were acceptable. Compared to RT + S, RT + L had good efficacy in the treatment of hepatocellular carcinoma with PVTT. Validation is needed in prospective studies with larger sample sizes.

Schlagwörter

Stichwörter der Autor:innen

PVTTVEGFhepatocellular carcinomaradiotherapytranscatheter arterial chemoembolization

Autor:innen und Institutionen

  • Jilin Provincial Key Laboratory of Radiation Oncology and Therapy, The First Hospital of Jilin University and College of Basic Medical Science, Jilin University, Changchun, China.
  • Department of Radiation Oncology, the First Hospital of Jilin University, Changchun, China.
  • NHC Key Laboratory of Radiobiology, School of Public Health of Jilin University, Changchun, China.

Zitieren

APA

Zhang, M., Zheng, Z., Ding, Q., Su, J., Xin, Y., & Jiang, X. (2024). Radiotherapy plus lenvatinib versus radiotherapy plus sorafenib for hepatocellular carcinoma with portal vein tumor thrombus: a retrospective study. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1458819

Vancouver

Zhang M, Zheng Z, Ding Q, Su J, Xin Y, Jiang X. Radiotherapy plus lenvatinib versus radiotherapy plus sorafenib for hepatocellular carcinoma with portal vein tumor thrombus: a retrospective study. Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1458819

BibTeX
@article{Zhang2024,
  author = {Zhang, Min and Zheng, Zhuangzhuang and Ding, Qiuhui and Su, Jing and Xin, Ying and Jiang, Xin},
  title = {Radiotherapy plus lenvatinib versus radiotherapy plus sorafenib for hepatocellular carcinoma with portal vein tumor thrombus: a retrospective study},
  journal = {Frontiers in Pharmacology},
  year = {2024},
  volume = {15},
  doi = {10.3389/fphar.2024.1458819}
}
Kostenlos starten →